Turn Therapeutics Inc.
NASDAQ:TTRXBiotechnology
-$0.17 today
- Market cap
- $271.79M
- Beta
- 2.77
- P/E (TTM)
- -45.0
- EPS (TTM)
- -$0.13
Volume 0.05M
Average 0.04M
TTRX Common Stock
The par or stated value of issued common shares, plus paid-in capital where reported together.
Turn Therapeutics Inc.NASDAQ: TTRX
Common Stock · Q1 FY2026 · quarter ended Mar 2026
Common stock of $2.98K in Q1 FY2026
Q1 FY2026 common stock was $2.98K.
Context
- Common stock amounted to 0.0% of total assets at the end of Q1 FY2026.
- Common stock increased in 2 of the last 2 fiscal years.
- FY2025 was the highest annual figure in the 3 fiscal years shown.
Sources:Balance SheetText generated from reported figures; not investment advice.
Common Stock history
USD · from the balance sheet
- Latest · FY2025
- 2.94K USD
- Year-over-year change
- +119.3%
- 2-year CAGR
- +49.1%
| Period | Period end | Common Stock | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 2.94K | +119.3% |
| FY2024 | 2024-12-31 | 1.34K | +1.4% |
| FY2023 | 2023-12-31 | 1.32K | — |
Common Stock vs competitors
How TTRX compares with its peers on the latest reported figures
- TTRX's Mar 2026 common stock of $2.98K is the 8th highest of the 9 companies compared; the peer median is $76.79K.
- Common stock amounts to 0.0% of total assets for TTRX, versus a peer median of 0.2%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $385K | +44.7% | -51.3% | 0.2% | |
| Apr 2026 | $339K | +5.3% | +2.2% | 2.3% | |
| Mar 2026 | $132.03K | +77.6% | +214.7% | 0.1% | |
| Mar 2026 | $90K | +45.2% | +45.9% | 0.2% | |
| Mar 2026 | $63.58K | +45.6% | +135.7% | 0.2% | |
| Mar 2026 | $14.67K | +11.2% | +3.6% | 0.1% | |
IRDOpus Genetics, Inc. | Mar 2026 | $7K | +40.0% | +51.8% | 0.0% |
TTRXTurn Therapeutics Inc. | Mar 2026 | $2.98K | — | — | 0.0% |
| Mar 2026 | $1K | +0.0% | +0.0% | 0.0% | |
| Peer median (excluding TTRX) | $76.79K | +42.4% | +24.7% | 0.2% | |
Competitors are the stored peer set for TTRX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Turn Therapeutics Inc.
NASDAQ:TTRX
Intrinsic Alpha fair value
Locked
Current Price
$8.89
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.